Financials in USD. Standardized financial statements.
A compact view of how Coeptis Therapeutics, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2005 | FY 2004 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $1.36M | $0 | $0 | $0 | $75,000 | $30,761 | $0 | $0 | $0 | $0 |
| Revenue Growth? | 0.0% | 0.0% | 0.0% | -100.0% | +143.8% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $180,625 | $0 | $0 | $0 | $0 | $964,217 | $0 | $0 | $0 | $0 |
| Gross Profit? | $1.18M | $0 | $0 | $0 | $75,000 | -$933,456 | $0 | $0 | $0 | $0 |
| Gross Margin? | +86.7% | 0.0% | 0.0% | 0.0% | +100.0% | -3034.5% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $14.23M | $10.05M | $21.49M | $34.20M | $14.12M | $5.93M | $0 | $0 | $308,305 | $10,077 |
| Operating Income? | -$13.04M | -$10.05M | -$21.49M | -$34.20M | -$14.05M | -$6.86M | $0 | $0 | -$308,000 | -$10,077 |
| EBITDA? | -$10.41M | -$9.38M | -$20.12M | -$36.35M | -$12.81M | -$8.68M | $171,860 | -$7,070 | -$344,000 | $2.65M |
| Income Before Tax | -$12.28M | -$10.88M | -$21.27M | -$37.57M | -$13.45M | -$9.16M | -$2,234 | -$7,073 | $0 | $2.65M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $36,000 | $0 |
| Net Income? | -$11.92M | -$10.68M | -$21.27M | -$37.57M | -$13.45M | -$9.16M | -$2,234 | -$7,073 | -$344,000 | $2.65M |
| EPS? | $-2.81 | $-5.65 | $-0.83 | $-2.87 | $-13.16 | $-0.45 | $-0.00 | $-0.01 | $-184.81 | $1421.16 |
| Diluted EPS? | $-2.81 | $-5.65 | $-0.83 | $-2.87 | $-13.16 | $-0.45 | $-0.00 | $-0.01 | $-184.81 | $1421.16 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality